Hypertriglyceridemia

References

Key articles

Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults. JAMA. 2002 Oct 9;288(14):1723-7. Abstract

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.Full text  Abstract

Donnelly KL, Smith CI, Schwartzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343-51. Abstract

Leaf DA, Parker DL, Schaad D. Changes in V02max, physical activity, and body fat with chronic exercise: effects on plasma lipids. Med Sci Sports Exerc. 1997 Sep;29(9):1152-9. Abstract

Reference articles

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) - executive summary. JAMA. 2001 May 16;285(19):2486-97. Abstract

2. Kushner PA, Cobble ME. Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med. 2016 Nov;128(8):848-58. Abstract

3. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.Full text  Abstract

4. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263-82.Full text  Abstract

5. Hegele RA, Ginsberg HN, Chapman MJ, et al.; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66.Full text  Abstract

6. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorder. N Engl J Med. 1967 Feb 2;276(5):273-81. Abstract

7. Mostaza JM, Vega GL, Snell P, et al. Abnormal metabolism of free fatty acids in hypertriglyceridemic men: apparent insulin resistance of adipose tissue. J Intern Med. 1998 Apr;243(4):265-74. Abstract

8. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults. JAMA. 2002 Oct 9;288(14):1723-7. Abstract

9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.Full text  Abstract

10. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001 Sep 12;286(10):1195-200. Abstract

11. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Med Clin North Am. 1982 Mar;66(2):455-68. Abstract

12. Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011 Mar 15;107(6):891-7.Full text  Abstract

13. Hubert HB, Feinleb M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May;67(5):968-77.Full text  Abstract

14. Zavaroni I, Dall'Aglio E, Alpi O, et al. Evidence for an independent relationship between insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985 Jun;55(3):259-66. Abstract

15. Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending and outpatient lipids clinic. Thyroid. 1999 Apr;9(4):365-8. Abstract

16. Avram MM, Fein PA, Antignani A, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med. 1989 Nov;87(5N):55-60N. Abstract

17. Donnelly KL, Smith CI, Schwartzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343-51. Abstract

18. Alves C de A, Lima DS. Cystic fibrosis-related dyslipidemia. J Bras Pneumol. 2008 Oct;34(10):829-37. Abstract

19. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation. 1998 Sep 1;98(9):829-30. Abstract

20. Dron J, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep. 2017 Jul;19(7):31.Full text  Abstract

21. Apstein MD, George BC. Serum lipids during the first year following acute spinal cord injury. Metabolism. 1998 Apr;47(4):367-70. Abstract

22. Zakim D, Alexander D, Sleisenger MH. The effect of ethanol on hepatic excretion of triglycerides into plasma. J Clin Invest. 1965;44:1115.

23. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med. 1989 Nov;87(5N):61-67N. Abstract

24. Salazar A, Mana J, Pinto X, et al. Low levels of high-density lipoprotein-cholesterol in patients with active sarcoidosis. Atherosclerosis. 1998 Jan;136(1):133-7. Abstract

25. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in women. Ann Intern Med. 1991 Dec 1;115(11):860-4. Abstract

26. Lardinois CK, Neuman SL. The effect of antihypertensive agents on lipids and lipoproteins. Arch Intern Med. 1988 Jun;148(6):1280-8. Abstract

27. Italian Registry of Antiretroviral Post-exposure Prophylaxis. Effects of short course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS. 2000 Oct 20;14(15):2407-8. Abstract

28. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007 May;92(5):1581-9. Abstract

29. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol. 2012 Feb;59(2):198-205. Abstract

30. Brunzell JD, Hazzard, WR, Porte D Jr, et al. Evidence for a common saturable triglyceride removal mechanism for chylomicron and very low density lipoproteins in man. J Clin Invest. 1973 Jul;52(7):1578-85.Full text  Abstract

31. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb. 1992 Aug;12(8):911-9. Abstract

32. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol. 2000 Jan 1;85(1):45-8. Abstract

33. Cao Y, Mauger DT, Pelkman CL, et al. Effects of moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-analysis of clinical trials in subjects with and without diabetes. J Clin Lipidol. 2009 Feb;3(1):19-32. Abstract

34. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007 Dec;7(12):787-96. Abstract

35. Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther. 2017 Feb;34(2):300-23.Full text  Abstract

36. Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.Full text  Abstract

37. Leaf DA, Parker DL, Schaad D. Changes in V02max, physical activity, and body fat with chronic exercise: effects on plasma lipids. Med Sci Sports Exerc. 1997 Sep;29(9):1152-9. Abstract

38. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.Full text  Abstract

39. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a Presidential Advisory from the American Heart Association. Circulation. 2017 Jul 18;136(3):e1-23. Abstract

40. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. Abstract

41. American College of Cardiology: ASCVD risk estimator plus

42. Wu J, Song Y, Li H, et al. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009 Dec;65(12):1169-74. Abstract

43. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009 Dec;65(12):1169-74. Abstract

44. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74.Full text  Abstract

45. Food and Drug Administration. Withdrawal of approval of indications related to the coadministration with statins in application for niacin extended-release tablets and fenofibric acid delayed-release capsules. April 2016 [internet publication].Full text

46. Sanders TA, Sullivan DR, Reeve J, et. al. Triglyceride-lowering effects of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis. 1985 Sep-Oct;5(5):459-65. Abstract

47. Patel AA, Budoff MJ. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):145-9. Abstract

48. Yokoyama M, Origasa H; JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J. 2003 Oct;146(4):613-20. Abstract

49. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008 Jan;121(1):10-2. Abstract

50. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 Sep-Oct;8(5):473-88.Full text  Abstract

51. Connor WE. The dietary treatment of hypertriglyceridemia. Med Clin North Am. 1982 Mar;66(2):485-518.

52. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-90. Abstract

53. Rizzo M, Christ ER, Rini GB, et al. The differential effects of thiazolidinediones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opin Pharmacother. 2008 Sep;9(13):2295-303. Abstract

54. Spanheimer R, Betteridge DJ, Tan MH, et al. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009 Jul 15;104(2):234-9. Abstract

55. Veterans Health Administration. VA/DoD clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction. December 2014 [internet publication].Full text

56. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Dec;45(12):3754-832.Full text  Abstract

57. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-333.Full text  Abstract

58. Academy of Nutrition and Dietetics (American Dietetic Association). Disorders of lipid metabolism: evidence-based nutrition practice guideline. 2011 [internet publication].Full text

59. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. Circulation. 2011 Mar 22;123(11):1243-62.Full text  Abstract

60. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. J Am Coll Cardiol. 2011 Nov 29;58(23):2432-46.Full text  Abstract

61. Rosenzweig JL, Ferrannini E, Grundy SM, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008 Oct;93(10):3671-89.Full text  Abstract

62. McCrindle BW, Urbina EM, Dennison BA, et al; American Heart Association. Drug therapy of high-risk lipid abnormalities in children and adolescents. Circulation. 2007 Apr 10;115(14):1948-67.Full text  Abstract

63. Lichtenstein AH, Appel LJ, Brands M, et al; American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006 Jul 4;114(1):82-96.Full text  Abstract

64. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Arteriosclerosis. 1998 Dec;141 Suppl 1:S57-62. Abstract

65. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9. Abstract

66. Frick MH, Elo O, Haapa K, et al. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. JAMA. 1987 Nov 12;317(20):1237-45. Abstract

67. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410-8.Full text  Abstract

Use of this content is subject to our disclaimer